1887

Abstract

Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative infections. Variant Creutzfeldt-Jakob disease (vCJD) and sporadic CJD (sCJD) are human TSEs that, in rare cases, have been transmitted by human-derived therapeutic products. There is a need for a blood test to detect infected donors, identify infected individuals in families with TSEs and monitor progression of disease in patients, especially during clinical trials. We prepared panels of blood from cynomolgus and rhesus macaques experimentally infected with vCJD, as a surrogate for human blood, to support assay development. We detected abnormal prion protein (PrP) in those blood samples using the protein misfolding cyclic amplification (PMCA) assay. PrP first appeared in the blood of pre-symptomatic cynomolgus macaques as early as 2 months post-inoculation (mpi). In contrast, PMCA detected PrP much later in the blood of two pre-symptomatic rhesus macaques, starting at 19 and 20 mpi, and in one rhesus macaque only when symptomatic, at 38 mpi. Once blood of either species of macaque became PMCA-positive, PrP persisted through terminal illness at relatively constant concentrations. Infectivity in buffy coat samples from terminally ill cynomolgus macaques as well as a sample collected 9 months before clinical onset of disease in one of the macaques was assayed in vCJD-susceptible transgenic mice. The infectivity titres varied from 2.7 to 4.3 infectious doses ml. We also screened macaque blood using a four-member panel of biomarkers for neurodegenerative diseases to identify potential non-PrP pre-symptomatic diagnostic markers. Neurofilament light-chain protein (NfL) increased in blood before the onset of clinical vCJD. Cumulatively, these data confirmed that, while PrP is the first marker to appear in blood of vCJD-infected cynomolgus and rhesus macaques, NfL might offer a useful, though less specific, marker for forthcoming neurodegeneration. These studies support the use of macaque blood panels to investigate PrP and other biomarkers to predict onset of CJD in humans.

Keyword(s): assay , biomarkers , blood , infectivity , macaque and prion
Funding
This study was supported by the:
  • U.S. Food and Drug Administration
    • Principle Award Recipient: NotApplicable
  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001764
2022-07-11
2024-12-09
Loading full text...

Full text loading...

/deliver/fulltext/jgv/103/7/jgv001764.html?itemId=/content/journal/jgv/10.1099/jgv.0.001764&mimeType=html&fmt=ahah

References

  1. Ironside JW. Variant Creutzfeldt-Jakob disease: an update. Folia Neuropathol 2012; 50:50–56 [PubMed]
    [Google Scholar]
  2. Will R. Variant Creutzfeldt-Jakob disease. Folia Neuropathol 2004; 42 Suppl A:77–83 [PubMed]
    [Google Scholar]
  3. Brown P, Brandel J-P, Sato T, Nakamura Y, MacKenzie J et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 2012; 18:901–907 [View Article] [PubMed]
    [Google Scholar]
  4. Bonda DJ, Manjila S, Mehndiratta P, Khan F, Miller BR et al. Human prion diseases: surgical lessons learned from iatrogenic prion transmission. Neurosurg Focus 2016; 41:E10 [View Article] [PubMed]
    [Google Scholar]
  5. Belay ED, Schonberger LB. Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Clin Lab Med 2002; 22:849–862 [View Article] [PubMed]
    [Google Scholar]
  6. Centers for Disease Control and Prevention Creutzfeldt-Jakob Disease, Classic (CJD); 2021 https://www.cdc.gov/prions/cjd/index.html
  7. Maddox RA, Person MK, Blevins JE, Abrams JY, Appleby BS et al. Prion disease incidence in the United States: 2003-2015. Neurology 2020; 94:e153–e157 [View Article] [PubMed]
    [Google Scholar]
  8. Hermann P, Appleby B, Brandel J-P, Caughey B, Collins S et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol 2021; 20:235–246 [View Article] [PubMed]
    [Google Scholar]
  9. Schmitz M, Dittmar K, Llorens F, Gelpi E, Ferrer I et al. Hereditary human prion diseases: an update. Mol Neurobiol 2017; 54:4138–4149 [View Article] [PubMed]
    [Google Scholar]
  10. Mead S, Tagliavini F. Clinical trials. Handb Clin Neurol 2018; 153:431–444 [View Article] [PubMed]
    [Google Scholar]
  11. Minikel EV, Zhao HT, Le J, O’Moore J, Pitstick R et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res 2020; 48:10615–10631 [View Article] [PubMed]
    [Google Scholar]
  12. Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13:150–158 [View Article] [PubMed]
    [Google Scholar]
  13. Rhoads DD, Wrona A, Foutz A, Blevins J, Glisic K et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. Neurology 2020; 95:e1017–e1026 [View Article] [PubMed]
    [Google Scholar]
  14. Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW et al. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods 2007; 4:645–650 [View Article] [PubMed]
    [Google Scholar]
  15. Chen B, Morales R, Barria MA, Soto C. Estimating prion concentration in fluids and tissues by quantitative PMCA. Nat Methods 2010; 7:519–520 [View Article] [PubMed]
    [Google Scholar]
  16. Kramm C, Soto P, Nichols TA, Morales R. Chronic wasting disease (CWD) prion detection in blood from pre-symptomatic white-tailed deer harboring PRNP polymorphic variants. Sci Rep 2020; 10:19763 [View Article] [PubMed]
    [Google Scholar]
  17. Salamat MKF, Blanco ARA, McCutcheon S, Tan KBC, Stewart P et al. Preclinical transmission of prions by blood transfusion is influenced by donor genotype and route of infection. PLoS Pathog 2021; 17:e1009276 [View Article] [PubMed]
    [Google Scholar]
  18. Concha-Marambio L, Chacon MA, Soto C. Preclinical detection of prions in blood of nonhuman primates infected with variant creutzfeldt-jakob disease. Emerg Infect Dis 2020; 26:34–43 [View Article] [PubMed]
    [Google Scholar]
  19. Bougard D, Brandel J-P, Bélondrade M, Béringue V, Segarra C et al. Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl Med 2016; 8:370 [View Article] [PubMed]
    [Google Scholar]
  20. Concha-Marambio L, Pritzkow S, Moda F, Tagliavini F, Ironside JW et al. Detection of prions in blood from patients with variant Creutzfeldt-Jakob disease. Sci Transl Med 2016; 8:370 [View Article] [PubMed]
    [Google Scholar]
  21. Bélondrade M, Nicot S, Mayran C, Bruyere-Ostells L, Almela F et al. Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldt-Jakob disease prions is strongly seed and substrate dependent. Sci Rep 2021; 11:4058 [View Article] [PubMed]
    [Google Scholar]
  22. McDowell KL, Nag N, Franco Z, Bu M, Piccardo P et al. Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent. Transfusion 2015; 55:405–412 [View Article] [PubMed]
    [Google Scholar]
  23. Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep 2016; 6:38737 [View Article] [PubMed]
    [Google Scholar]
  24. Zerr I, Villar-Piqué A, Hermann P, Schmitz M, Varges D et al. Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther 2021; 13:86 [View Article] [PubMed]
    [Google Scholar]
  25. Thompson AGB, Luk C, Heslegrave AJ, Zetterberg H, Mead SH et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry 2018; 89:955–961 [View Article] [PubMed]
    [Google Scholar]
  26. Vallabh SM, Minikel EV, Williams VJ, Carlyle BC, McManus AJ et al. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med 2020; 18:140 [View Article] [PubMed]
    [Google Scholar]
  27. Nemecek J, Nag N, Carlson CM, Schneider JR, Heisey DM et al. Red-backed vole brain promotes highly efficient in vitro amplification of abnormal prion protein from macaque and human brains infected with variant Creutzfeldt-Jakob disease agent. PLoS One 2013; 8:e78710 [View Article] [PubMed]
    [Google Scholar]
  28. Castilla J, Gutiérrez Adán A, Brun A, Pintado B, Ramírez MA et al. Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol 2003; 148:677–691 [View Article] [PubMed]
    [Google Scholar]
  29. Bett C, Piccardo P, Cervenak J, Torres JM, Asher DM et al. Both murine host and inoculum modulate expression of experimental variant Creutzfeldt-Jakob disease. J Gen Virol 2018; 99:422–433 [View Article] [PubMed]
    [Google Scholar]
  30. Medikonia Limited Quanterix; 2022 https://www.medikonia.com/quanterix
  31. Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368:2226–2230 [View Article] [PubMed]
    [Google Scholar]
  32. Lasmézas CI, Deslys JP, Demaimay R, Adjou KT, Lamoury F et al. BSE transmission to macaques. Nature 1996; 381:743–744 [View Article] [PubMed]
    [Google Scholar]
  33. Krasemann S, Neumann M, Geissen M, Bodemer W, Kaup FJ et al. Preclinical deposition of pathological prion protein in muscle of experimentally infected primates. PLoS One 2010; 5:e13906 [View Article] [PubMed]
    [Google Scholar]
  34. Sawyer EB, Edgeworth JA, Thomas C, Collinge J, Jackson GS. Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease. Sci Rep 2015; 5:17742 [View Article] [PubMed]
    [Google Scholar]
  35. Glatzel M, Pekarik V, Lührs T, Dittami J, Aguzzi A. Analysis of the prion protein in primates reveals a new polymorphism in codon 226 (Y226F). Biol Chem 2002; 383:1021–1025 [View Article] [PubMed]
    [Google Scholar]
  36. Murayama Y, Masujin K, Imamura M, Ono F, Shibata H et al. Ultrasensitive detection of PrP(Sc) in the cerebrospinal fluid and blood of macaques infected with bovine spongiform encephalopathy prion. J Gen Virol 2014; 95:2576–2588 [View Article] [PubMed]
    [Google Scholar]
  37. Lacroux C, Comoy E, Moudjou M, Perret-Liaudet A, Lugan S et al. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog 2014; 10:e1004202 [View Article] [PubMed]
    [Google Scholar]
  38. Brown P, Cervenáková L, McShane LM, Barber P, Rubenstein R et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169–1178 [View Article] [PubMed]
    [Google Scholar]
  39. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43:1687–1694 [View Article] [PubMed]
    [Google Scholar]
  40. Teitsdottir UD, Jonsdottir MK, Lund SH, Darreh-Shori T, Snaedal J et al. Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions. Alzheimers Res Ther 2020; 12:92 [View Article] [PubMed]
    [Google Scholar]
  41. Shahim P, Politis A, van der Merwe A, Moore B, Ekanayake V et al. Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology 2020; 95:e623–e636 [View Article] [PubMed]
    [Google Scholar]
  42. Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 2018; 8:14798 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.001764
Loading
/content/journal/jgv/10.1099/jgv.0.001764
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error